Nexpoint Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-1,893,891
| Closed | -$28.7M | – | 154 |
|
|
2022
Q3 | $28.7M | Buy |
1,893,891
+1,584,113
| +511% | +$18.4M | 1.92% | 20 |
|
|
2022
Q2 | $2.32M | Hold |
309,778
| – | – | 0.21% | 55 |
|
|
2022
Q1 | $2.82M | Hold |
309,778
| – | – | 0.36% | 39 |
|
|
2021
Q4 | $2.17M | Hold |
309,778
| – | – | 0.31% | 57 |
|
|
2021
Q3 | $3.53M | Hold |
309,778
| – | – | 0.61% | 32 |
|
|
2021
Q2 | $4.96M | Sell |
309,778
-87,220
| -22% | -$1.5M | 1.08% | 25 |
|
|
2021
Q1 | $7.09M | Sell |
396,998
-45,802
| -10% | -$791K | 1.85% | 15 |
|
|
2020
Q4 | $5.98M | Hold |
442,800
| – | – | 1.97% | 12 |
|
|
2020
Q3 | $5.21M | Hold |
442,800
| – | – | 1.18% | 14 |
|
|
2020
Q2 | $6.54M | Buy |
442,800
+62,390
| +16% | +$923K | 1.47% | 13 |
|
|
2020
Q1 | $5.14M | Sell |
380,410
-449,200
| -54% | -$8.52M | 0.97% | 16 |
|
|
2019
Q4 | $20.1M | Buy |
829,610
+21,219
| +3% | +$439K | 1.52% | 13 |
|
|
2019
Q3 | $15.5M | Buy |
+808,391
| New | +$18.5M | 0.97% | 18 |
|
Nexpoint Asset Management's AERI Position: Q4 2022 in Review
Nexpoint Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 1,893,891 shares — an estimated $28.7M sold.
Nexpoint Asset Management first reported a position in AERI in Q3 2019 and held it in 13 quarters. The position peaked at $28.7M in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Nexpoint Asset Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Nexpoint Asset Management sold 1,893,891 Aerie Pharmaceuticals shares in Q4 2022, an estimated $28.7M.
- Nexpoint Asset Management first reported a position in Aerie Pharmaceuticals in Q3 2019 and held it in 13 quarters.
- Nexpoint Asset Management's Aerie Pharmaceuticals position peaked at $28.7M in Q3 2022.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Nexpoint Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.